# Chris Liu

> Chris Liu is a Series A investor at Horizons Ventures (London) backing Health Care and Medical. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Horizons Ventures](https://shizune.co/investors/profile/horizons-ventures)
- Location: London, United Kingdom
- Total investments: 10
- Last investment: Mar 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chriscsliu/

Chris Liu is a Series A investor at Horizons Ventures in London focused on Health Care and Medical. Chris Liu - Special Projects @ Horizons Ventures

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 30% |
| Medical | 2 | 20% |
| Biotechnology | 2 | 20% |
| Medical Device | 2 | 20% |
| Artificial Intelligence | 2 | 20% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 30% |
| Series B | 3 | 30% |
| Seed | 2 | 20% |
| Series C | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cauldron Ferm | Cauldron Ferm is a bio-acceleration process that exponentially scales up any precision fermented prototype to commercial quantities faster and with a lower cost of goods than any traditional production method. | $13.3M | Series A | Mar 24, 2026 |  |
| Harrison.ai | Harrison.ai is a clinician-led healthcare AI company using deep learning to improve the odds of IVF success for thousands of patients. The company leverages deep learning to solve the biggest challenges in healthcare and seeks to improve patient outcomes. It empowers physicians and healthcare providers with customized AI-enabled tools thatintegrate into existing clinical workflows which ultimately lead to improved patient outcomes.Harrison.ai uses the deskside DGX Station for experimentation, research, and development. The company uniquely combines exceptional deep learning expertise with clinical experience to develop and deploy healthcare AI solutions. Harrison.ai’s IVY deep learning model analyzes the full five-day video feed from an embryo scope, helping it surpass the performance of AI tools that provide insights based on still images.Harrison.ai's mission is to continuously innovate and commercialize more efficient and more affordable healthcare products and services to healthcare providers and patients.Harrison.ai was founded in 2018 and is headquartered in Barongarook, Victoria, Australia. | $112M | Series C | Feb 11, 2025 |  |
| Cauldron Ferm | Cauldron Ferm is a bio-acceleration process that exponentially scales up any precision fermented prototype to commercial quantities faster and with a lower cost of goods than any traditional production method. | $6.2M | Series A | Mar 18, 2024 |  |
| Cauldron Ferm | Cauldron Ferm is a bio-acceleration process that exponentially scales up any precision fermented prototype to commercial quantities faster and with a lower cost of goods than any traditional production method. | $7M | Seed | Mar 28, 2023 |  |
| Loam Bio | Loam Bio is a developer of microbial carbon sequestration technology for soil carbon restoration. Crops can be inoculated with symbiotic microorganisms that live in a mutualistic relationship with crops and build organic carbon in the soil, allowing farmers to improve the host plant's fertility and disease resistance while also assisting thesoil around the plant's roots to store carbon more effectively, resulting in proper quality soil for future planting. Loam Bio was established in 2019 by Guy Hudson. | $77.1M | Series B | Feb 13, 2023 |  |
| Fertilis | Fertilis is a company that makes in vitro fertilization (IVF) less stressful and more successful for patients and clinicians. | $2M | Seed | Jan 11, 2022 |  |
| Harrison.ai | Harrison.ai is a clinician-led healthcare AI company using deep learning to improve the odds of IVF success for thousands of patients. The company leverages deep learning to solve the biggest challenges in healthcare and seeks to improve patient outcomes. It empowers physicians and healthcare providers with customized AI-enabled tools thatintegrate into existing clinical workflows which ultimately lead to improved patient outcomes.Harrison.ai uses the deskside DGX Station for experimentation, research, and development. The company uniquely combines exceptional deep learning expertise with clinical experience to develop and deploy healthcare AI solutions. Harrison.ai’s IVY deep learning model analyzes the full five-day video feed from an embryo scope, helping it surpass the performance of AI tools that provide insights based on still images.Harrison.ai's mission is to continuously innovate and commercialize more efficient and more affordable healthcare products and services to healthcare providers and patients.Harrison.ai was founded in 2018 and is headquartered in Barongarook, Victoria, Australia. | $91.7M | Series B | Dec 01, 2021 |  |
| Loam Bio | Loam Bio is a developer of microbial carbon sequestration technology for soil carbon restoration. Crops can be inoculated with symbiotic microorganisms that live in a mutualistic relationship with crops and build organic carbon in the soil, allowing farmers to improve the host plant's fertility and disease resistance while also assisting thesoil around the plant's roots to store carbon more effectively, resulting in proper quality soil for future planting. Loam Bio was established in 2019 by Guy Hudson. | $30.1M | Series A | Oct 28, 2021 |  |
| Prospection | Prospection is a Pioneer in healthcare data analytics. Using predictive analytics and machine learning with real world healthcare data to unearth insights that help research, develop and target better healthcare outcomes for patients. Founded out of Sydney’s Cicada Innovations in 2012, Prospection works with government, pharmaceutical companies andthe medical community across more than 90 therapy programs, including immuno-oncology, Diabetes, Respiratory, HIV and hepatitis, in Australia, Japan, Asia Pacific, UK and USA. | $33.1M | Series B | Sep 13, 2021 |  |
| Prospection | Prospection is a Pioneer in healthcare data analytics. Using predictive analytics and machine learning with real world healthcare data to unearth insights that help research, develop and target better healthcare outcomes for patients. Founded out of Sydney’s Cicada Innovations in 2012, Prospection works with government, pharmaceutical companies andthe medical community across more than 90 therapy programs, including immuno-oncology, Diabetes, Respiratory, HIV and hepatitis, in Australia, Japan, Asia Pacific, UK and USA. | $6.6M | Series A | Feb 21, 2020 |  |

10 of 10 investments shown.

## Co-investors
- [Main Sequence Ventures](https://shizune.co/investors/profile/main-sequence-ventures) — VC Fund, 7 deals together
- [Clean Energy Finance Corporation](https://shizune.co/investors/profile/clean-energy-finance-corp) — VC Fund, 3 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 3 deals together
- [Acre Venture Partners](https://shizune.co/investors/profile/acre-venture-partners) — VC Fund, 2 deals together
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund, 2 deals together
- [Grok Ventures](https://shizune.co/investors/profile/grok-ventures) — VC Fund, 2 deals together

## About Horizons Ventures

VC Fund · Hong Kong, Hong Kong

Horizons Ventures focuses on investing in disruptive and technology-focused start-ups. The firm was founded in 1999 and is based in Hong Kong. Some of the latest exits are Skype, Siri, Facebook, Summly, and Waze.

5 contacts available at Horizons Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Bart Swanson | Advisor | https://shizune.co/investors/profile/bart-swanson |
| Chris Liu | Special Projects | https://shizune.co/investors/profile/chirs-liu |
| Patrick Poon | Project Director | https://shizune.co/investors/profile/patrick-poon |
| Debbie Chang | Founder | https://shizune.co/investors/profile/debbie-chang |
| Frances Kang | Director | https://shizune.co/investors/profile/frances-kang |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Chris Liu invest in?

Chris Liu invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Liu last invest?

The most recent investment recorded for Chris Liu closed in Mar 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co